All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
CAART-LX221 | Anti-Thyrotropin receptor (M22) h(CD28-CD3ζ) CAART, pCDCAAR1 | Human | M22 | Human | scFv-CD28-CD3ζ | Lentiviral vector | B cell | ||
CAART-LX222 | Anti-Thyrotropin receptor (XHM496) h(CD28-CD3ζ) CAART, pCDCAAR1 | Human | XHM496 | Human | scFv-CD28-CD3ζ | Lentiviral vector | B cell | ||
CAART-LX223 | Anti-Thyrotropin receptor (XHM497) h(CD28-CD3ζ) CAART, pCDCAAR1 | Human | XHM497 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | B cell | ||
CAART-LX224 | Anti-Thyrotropin receptor (7G10) h(CD28-CD3ζ) CAART, pCDCAAR1 | Human | 7G10 | Hamster | scFv-CD28-CD3ζ | Lentiviral vector | B cell | ||
CAART-LX225 | Anti-Thyrotropin receptor (MS1) h(CD28-CD3ζ) CAART, pCDCAAR1 | Human | MS1 | Hamster | scFv-CD28-CD3ζ | Lentiviral vector | B cell | ||
CAART-LX226 | Anti-Thyrotropin receptor (M22) h(4-1BB-CD3ζ) CAART, pCDCAAR1 | Human | M22 | Human | scFv-4-1BB-CD3ζ | Lentiviral vector | B cell | ||
CAART-LX227 | Anti-Thyrotropin receptor (XHM496) h(4-1BB-CD3ζ) CAART, pCDCAAR1 | Human | XHM496 | Human | scFv-4-1BB-CD3ζ | Lentiviral vector | B cell | ||
CAART-LX228 | Anti-Thyrotropin receptor (XHM497) h(4-1BB-CD3ζ) CAART, pCDCAAR1 | Human | XHM497 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | B cell | ||
CAART-LX229 | Anti-Thyrotropin receptor (7G10) h(4-1BB-CD3ζ) CAART, pCDCAAR1 | Human | 7G10 | Hamster | scFv-4-1BB-CD3ζ | Lentiviral vector | B cell | ||
CAART-LX230 | Anti-Thyrotropin receptor (MS1) h(4-1BB-CD3ζ) CAART, pCDCAAR1 | Human | MS1 | Hamster | scFv-4-1BB-CD3ζ | Lentiviral vector | B cell |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION